Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AKBA Stock Forecast 2026-2027
$1.38
Current Price
$366.21M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AKBA Price Targets
+334.8%
To High Target of $6.00
+262.3%
To Median Target of $5.00
+262.3%
To Low Target of $5.00
AKBA Price Momentum
-7.4%
1 Week Change
-14.3%
1 Month Change
-28.9%
1 Year Change
-14.3%
Year-to-Date Change
-66.2%
From 52W High of $4.08
+5.3%
From 52W Low of $1.31
📊 TOP ANALYST CALLS
Did AKBA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Akebia is one of their latest high-conviction picks.
Latest AKBA Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, AKBA has a bullish consensus with a median price target of $5.00 (ranging from $5.00 to $6.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $1.38, the median forecast implies a 262.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Caufield at HC Wainwright & Co., projecting a 334.8% upside. Conversely, the most conservative target is provided by Julian Harrison at BTIG, suggesting a 262.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AKBA Analyst Ratings
5
Buy
0
Hold
0
Sell
AKBA Price Target Range
Low
$5.00
Average
$5.00
High
$6.00
Current: $1.38
Latest AKBA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AKBA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $6.00 |
| Dec 2, 2025 | BTIG | Julian Harrison | Buy | Reiterates | $5.00 |
| Oct 30, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Maintains | $6.00 |
| Oct 29, 2025 | BTIG | Julian Harrison | Buy | Maintains | $5.00 |
| Jun 4, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Assumes | $8.00 |
| Apr 28, 2025 | Leerink Partners | Roanna Ruiz | Outperform | Initiates | $7.00 |
| Apr 4, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Apr 1, 2025 | Jefferies | Roger Song | Buy | Initiates | $6.00 |
| Mar 14, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $6.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Jan 23, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Jan 14, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Oct 23, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Oct 10, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Oct 8, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Sep 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Aug 12, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $7.50 |
| Mar 28, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $6.00 |
| Mar 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Nov 29, 2023 | BTIG | Julian Harrison | Buy | Assumes | $4.00 |
Akebia Therapeutics Inc. (AKBA) Competitors
The following stocks are similar to Akebia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Akebia Therapeutics Inc. (AKBA) Financial Data
Akebia Therapeutics Inc. has a market capitalization of $366.21M with a P/E ratio of -4.2x. The company generates $225.07M in trailing twelve-month revenue with a -7.1% profit margin.
Revenue growth is +57.0% quarter-over-quarter, while maintaining an operating margin of +7.6% and return on equity of +141.1%.
Valuation Metrics
Market Cap
$366.21M
Enterprise Value
$404.08M
P/E Ratio
-4.2x
PEG Ratio
0.0x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
+57.0%
Gross Margin
+84.0%
Operating Margin
+7.6%
Net Margin
-7.1%
EPS Growth
+57.0%
Financial Health
Cash/Price Ratio
+45.4%
Current Ratio
1.9x
Debt/Equity
478.5x
ROE
+141.1%
ROA
+4.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Akebia Therapeutics Inc. (AKBA) Business Model
About Akebia Therapeutics Inc.
What They Do
Develops therapies for kidney disease.
Business Model
Akebia Therapeutics generates revenue by developing and commercializing innovative therapies for kidney disease, particularly chronic kidney disease (CKD). The company’s lead product, vadadustat, targets anemia associated with CKD and is marketed through partnerships with academic institutions and other pharmaceutical companies, enhancing its market reach.
Additional Information
Headquartered in Cambridge, Massachusetts, Akebia is committed to addressing unmet medical needs in nephrology, positioning itself as a significant player in the biopharmaceutical sector focused on improving patient lives through scientific innovation.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
181
CEO
Mr. John P. Butler MBA
Country
United States
IPO Year
2014
Website
www.akebia.comAkebia Therapeutics Inc. (AKBA) Latest News & Analysis
Latest News
Quick Summary
Akebia Therapeutics plans to enhance Vafseo prescribing for 275,000 patients. It has begun a Phase 2 trial for Praliciguat in FSGS and will start another rare kidney disease trial in 2H 2026.
Why It Matters
Akebia Therapeutics' advancements in Vafseo prescriptions and upcoming clinical trials could enhance market position and revenue potential, influencing stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Akebia Therapeutics granted options to purchase 197,900 shares of common stock to a new employee as an inducement for joining the company, complying with Nasdaq rules.
Why It Matters
The stock option grant indicates Akebia's growth strategy and commitment to talent acquisition, potentially impacting stock performance and market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Akebia Therapeutics has initiated a Phase 2 clinical trial for praliciguat, an oral treatment for biopsy-confirmed FSGS, with future assessments planned for other rare kidney diseases.
Why It Matters
The initiation of a Phase 2 trial for praliciguat signals potential advancements in treatment for rare kidney diseases, which could enhance Akebia's market position and drive stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Akebia Therapeutics has acquired a C3d-Factor H fusion protein complement inhibitor and initiated a Phase 2 trial for Praliciguat, targeting rare kidney diseases, both set to start in 2026.
Why It Matters
Akebia Therapeutics' acquisition and planned trials for kidney disease treatments signal potential growth in their pipeline, possibly impacting stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Q32 Bio Sells Complement Inhibitor ADX-097
1 month ago
Quick Summary
Q32 Bio sold its Phase 2 complement inhibitor, ADX-097, to Akebia for $12 million upfront, with potential total payments of $592 million. The sale supports its focus on bempikibart for alopecia areata.
Why It Matters
The asset sale and milestone payments enhance Q32 Bio's financial stability and focus on bempikibart, potentially increasing future revenue and investor confidence in its pipeline.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Akebia Therapeutics (Nasdaq: AKBA) will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on December 2 at 4:30 PM EST.
Why It Matters
Akebia's participation in a prominent healthcare conference could signal potential developments or partnerships, impacting stock performance and investor sentiment in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AKBA Stock
What is Akebia Therapeutics Inc.'s (AKBA) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Akebia Therapeutics Inc. (AKBA) has a median price target of $5.00. The highest price target is $6.00 and the lowest is $5.00.
Is AKBA stock a good investment in 2026?
According to current analyst ratings, AKBA has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AKBA stock?
Wall Street analysts predict AKBA stock could reach $5.00 in the next 12 months. This represents a 262.3% increase from the current price of $1.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Akebia Therapeutics Inc.'s business model?
Akebia Therapeutics generates revenue by developing and commercializing innovative therapies for kidney disease, particularly chronic kidney disease (CKD). The company’s lead product, vadadustat, targets anemia associated with CKD and is marketed through partnerships with academic institutions and other pharmaceutical companies, enhancing its market reach.
What is the highest forecasted price for AKBA Akebia Therapeutics Inc.?
The highest price target for AKBA is $6.00 from Matthew Caufield at HC Wainwright & Co., which represents a 334.8% increase from the current price of $1.38.
What is the lowest forecasted price for AKBA Akebia Therapeutics Inc.?
The lowest price target for AKBA is $5.00 from Julian Harrison at BTIG, which represents a 262.3% increase from the current price of $1.38.
What is the overall AKBA consensus from analysts for Akebia Therapeutics Inc.?
The overall analyst consensus for AKBA is bullish. Out of 10 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are AKBA stock price projections?
Stock price projections, including those for Akebia Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 5:34 AM UTC